2023 Annual Conference On-Demand Complete Conference Bundle

Get It!

Welcome to the Annual Conference 2023 On-Demand Conference Sessions!
The sessions in this bundle were presented live in Phoenix, AZ on March 29 - April 1, 2023.

Complete Conference Bundle Contents

  1. 2023 Annual Conference Posters
  2. (BC1) Updates in Early-Stage Breast Cancer – 1.0 BCOP & 1.0 ACPE CE
  3. (101) Updates in the Management of Follicular and Mantle Cell Lymphomas – 1.0 ACPE CE
  4. (102) Completed Research Platform Sessions – 1.0 ACPE CE
    1. Bruton Tyrosine Kinase (BTK) Inhibitors: Real World Clinical Outcomes in a Diverse Patient Population at a Large Safety Net Hospital
    2. Clinical Pharmacist-Initiated Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia
    3. Knowledge Gaps for Cancer Therapy-Related Cardiovascular Toxicities
    4. Optimizing Corticosteroid Utilization for Immune-related Adverse Events at a Community Oncology Practice
  5. (103) Significant Updates in Oncology – 1.0 ACPE CE
  6. (BC2) Updates in Hepatocellular Carcinoma – 1.0 BCOP & 1.0 ACPE CE
  7. (BC3) The Constant Gardener: The Evolving Landscape of Early Non-Small Cell Lung Cancer – 1.25 BCOP & 1.25 ACPE CE
  8. (BC4) The Great Debate: Graft Versus Host Disease (GVHD) Prophylaxis Strategies (Encore) – 1.25 BCOP & 1.25 ACPE CE
  9. (201) Practical Considerations for Clinicians – 1.0 ACPE CE
    1. Considerations in Opioid Tapering in Cancer Survivors
    2. What’s the Risk? Update on the Safe Use of Medicines in G6PD Deficiency
  10. (202) Updates in Hematology – 1.0 ACPE CE
    1. Current Approaches in the Management of Mixed Phenotype Acute Leukemia (MPAL)
    2. Polatuzumab-vedotin in Upfront Treatment of DLBCL: Overview of POLARIX Trial and Financial Considerations
  11. (203) Practice Management – 1.0 ACPE CE
    1. From Blame & Shame We Overcame: Establishing a Multidisciplinary Oncology Medication Safety Committee
    2. Treatment Site of Care Initiatives: Balancing Safety, Quality and Cost
  12. (204) HOPA-ASCO Quality Training Program (QTP) 6-month Program Participants Panel Discussion – 1.25 ACPE CE
  13. (205) Controversies in Precision Oncology: Interpreting the Grey Areas – 1.25 ACPE CE  
  14. (206) Optimizing Decision-Making for Treatment of Metastatic Renal Cell Carcinoma (mRCC): Balancing Evidence and Care Issues – 1.25 ACPE CE
  15. (BC5) Turning Up the Heat on Melanoma: Exploring Novel Immunotherapies in the Classic “Hot” Tumor – 1.0 BCOP & 1.0 ACPE CE
  16. (BC6) Giving orphan drugs a home: A case-based approach to the management of rare leukemic entities – 1.25 BCOP & 1.25 ACPE CE           
  17. (301) Significant Updates in Hematology – 1.0 ACPE CE     
  18. (302) Updates in Medical Oncology – GI – 1.0 ACPE CE
    1. Gaining Traction: Novel Targets and Treatment Strategies in Biliary Tract Cancer
    2. Microsatellite Instability in Early-Stage Colorectal Cancer: Are the Data Strong or Still Shaky?
  19. (303) Pharmacogenetics & Precision Medicine – 1.0 ACPE CE
    1. Clinical Utility of Germline Pharmacogenetic Testing in Patients with Cancer
    2. The Chicken or the Egg? Adverse Effect Management for Novel Drug Combinations in the Era of Oncology Precision Medicine
  20. (304) Non-Malignant Hematology – 1.0 ACPE CE
    1. Grab that Iron! Practical Considerations of Iron Chelation
    2. What’s Cooler Than Being Cool: Updates in Cold Agglutinin Disease 
  21. (305) Research Grant Award: Remote patient-reported quality of life outcomes in patients on oral anti-cancer therapy – 1.0 ACPE CE
  22. (306) Incorporating Sexual Orientation and Gender Identity Data into Oncology Patient Care – 1.25 ACPE CE
  23. (307) Three's a Crowd: Triplet Therapy for Metastatic Prostate Cancer – 1.0 ACPE CE
  24. (308) Beyond the Title: The Accidental or New Leader – 1.0 ACPE CE   
  25. (BC7) What's New Down Under? Updates in Gynecologic Malignancy – 1.25 BCOP & 1.25 ACPE CE
  26. (401) Postmarketing Safety in Oncology: An Overview of Pharmacovigilance at the FDA – 1.0 ACPE CE
  27. (402) How Do I Compare? Results of the Oncology Practice Landscape Survey from the Practice Outcomes and Professional Benchmarking Committee – 1.0 ACPE CE
  28. (403) Position Justifications: Justifying the Return on Investment – 1.0 ACPE CE  
  29. (404) Pediatric Clinical Pearls – 1.0 ACPE CE
    1. SOS…Defibrotide Prophylaxis for the Prevention of Sinusoidal Obstruction Syndrome in pediatric stem cell
    2. Spare a Thought for Asparaginase: Updates on Asparaginase
    3. High Impact Pharmacogenomics in Pediatrics
    4. Blast Off! A Review of Monoclonal Antibodies in Neuroblastoma Treatment
  30. (405) Investigational Drug Updates: Intratumoral Injections Bring Cancer Treatment Local – 1.0 ACPE CE
  31. (406) Updates in Amyloidosis – 1.0 ACPE CE
Get It!